Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4796441
Max Phase: Preclinical
Molecular Formula: C131H207IN34O30
Molecular Weight: 2865.21
Molecule Type: Unknown
Associated Items:
ID: ALA4796441
Max Phase: Preclinical
Molecular Formula: C131H207IN34O30
Molecular Weight: 2865.21
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](Cc2ccc(I)cc2)C(=O)N2CCC[C@H]2C(=O)N[C@H](Cc2ccc(-c3ccccc3)cc2)C(=O)O)C[C@@H]2CCCC[C@@H]21)N(C)C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCCNC(=N)N)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O
Standard InChI: InChI=1S/C131H207IN34O30/c1-82(2)71-104(121(184)162-100(78-167)118(181)159-97(75-89-76-143-81-151-89)117(180)154-90(34-21-24-56-133)113(176)150-77-111(173)166-101-39-20-19-33-87(101)74-105(166)122(185)160-98(72-84-46-50-88(132)51-47-84)125(188)165-64-30-41-103(165)120(183)161-99(127(191)192)73-83-44-48-86(49-45-83)85-31-15-14-16-32-85)163(3)123(186)94(38-28-60-149-131(141)142)158-119(182)102-40-29-63-164(102)124(187)95(36-23-26-58-147-129(137)138)157-116(179)93(52-54-106(134)168)156-115(178)92(37-27-59-148-130(139)140)155-114(177)91(35-22-25-57-146-128(135)136)152-110(172)80-196-70-68-194-66-62-145-109(171)79-195-69-67-193-65-61-144-107(169)55-53-96(126(189)190)153-108(170)42-17-12-10-8-6-4-5-7-9-11-13-18-43-112(174)175/h14-16,31-32,44-51,76,81-82,87,90-105,167H,4-13,17-30,33-43,52-75,77-80,133H2,1-3H3,(H2,134,168)(H,143,151)(H,144,169)(H,145,171)(H,150,176)(H,152,172)(H,153,170)(H,154,180)(H,155,177)(H,156,178)(H,157,179)(H,158,182)(H,159,181)(H,160,185)(H,161,183)(H,162,184)(H,174,175)(H,189,190)(H,191,192)(H4,135,136,146)(H4,137,138,147)(H4,139,140,148)(H4,141,142,149)/t87-,90-,91-,92+,93-,94+,95-,96-,97-,98-,99+,100-,101-,102-,103-,104-,105-/m0/s1
Standard InChI Key: UQTHMRJPWUIRTN-XCMRIGOXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2865.21 | Molecular Weight (Monoisotopic): 2863.4762 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Reed AB,Lanman BA,Holder JR,Yang BH,Ma J,Humphreys SC,Wang Z,Chan JCY,Miranda LP,Swaminath G,Allen JG. (2020) Half-life extension of peptidic APJ agonists by N-terminal lipid conjugation., 30 (21.0): [PMID:32858124] [10.1016/j.bmcl.2020.127499] |
Source(1):